Home » Stocks » BCYC

Bicycle Therapeutics PLC (BCYC)

Stock Price: $25.27 USD 0.33 (1.32%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $25.40 +0.13 (0.51%) Feb 26, 5:06 PM
Market Cap 538.37M
Revenue (ttm) 11.82M
Net Income (ttm) -37.98M
Shares Out 19.43M
EPS (ttm) -4.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $25.27
Previous Close $24.94
Change ($) 0.33
Change (%) 1.32%
Day's Open 24.86
Day's Range 23.80 - 25.98
Day's Volume 96,553
52-Week Range 10.26 - 33.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 month ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary...

Business Wire - 1 month ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 3 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 3 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on ...

Business Wire - 3 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 3 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 3 months ago

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 4 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 4 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 4 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

GuruFocus - 5 months ago

Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed this week his firm upped its stake in Bicycle Therapeutics PLC (NASDAQ:BCYC) by 175.4%.

Business Wire - 5 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 5 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 5 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 5 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 5 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 6 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 6 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 6 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary...

Zacks Investment Research - 8 months ago

Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Business Wire - 8 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

Business Wire - 8 months ago

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietar...

The Motley Fool - 8 months ago

This biotech company was founded by a Nobel laureate.

The Motley Fool - 10 months ago

Clinical trial successes could send shares of these drugmakers screaming higher.

Other stocks mentioned: BTAI, IGMS
Zacks Investment Research - 10 months ago

Bicycle Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 10 months ago

Is (BCYC) Outperforming Other Medical Stocks This Year?

The Motley Fool - 11 months ago

These five biotech stocks could post life-changing gains for early-bird investors.

Other stocks mentioned: CPRX, FOLD, INO, NVAX
Zacks Investment Research - 11 months ago

Top Ranked Momentum Stocks to Buy for March 16th

Other stocks mentioned: CODX
Zacks Investment Research - 11 months ago

Bicycle Therapeutics PLC Sponsored ADR (BCYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher ...

Zacks Investment Research - 11 months ago

Is (BCYC) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 11 months ago

Top Ranked Momentum Stocks to Buy for March 13th

Other stocks mentioned: GSX, RCUS, VIRT
The Motley Fool - 11 months ago

The coronavirus induced sell-off has created a number of attractive buying opportunities.

Other stocks mentioned: ABBV, AGEN, APHA, BCEL, BMY, CPRX, CRNX, FOLD, GWPH, OGI, PFE, RCUS, SRPT
Seeking Alpha - 11 months ago

Bicycle's Technology Uses 2-Step Approach To Treating Cancer And Many Other Diseases

The Motley Fool - 1 year ago

These two clinical-stage biotechs could yield exponential returns for early investors.

Other stocks mentioned: NVAX
The Motley Fool - 1 year ago

These top growth stocks could dramatically improve your financial wellbeing.

Other stocks mentioned: ADAP, AMRN, APHA, NVAX, PBYI
Seeking Alpha - 1 year ago

Bicycle Therapeutics: Early Stage Platform Technology Play With Multiple Upside Drivers

Seeking Alpha - 1 year ago

Bicycle Therapeutics: A Disruptive New Entrant To The Vast Targeted Cancer Treatment Space

Seeking Alpha - 1 year ago

Bicycle peptides are fully synthetic short peptides constrained to form two loops using a chemical connector compound known as a scaffold, which stabilizes their structural geometry.

Benzinga - 1 year ago

Shares of Bicycle Therapeutics PLC, which debuted on Wall Street in May, traded higher on Monday morning.

Market Watch - 1 year ago

Bicycle Therapeutics Ltd. shares soared 29% in premarket trade Monday, after the company announced positive results in a trial of a treatment for diabetic macular edema, or DME, a disease tha...

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune c... [Read more...]

Industry
Biotechnology
IPO Date
May 23, 2019
CEO
Kevin Lee
Employees
81
Stock Exchange
NASDAQ
Ticker Symbol
BCYC
Full Company Profile

Financial Performance

In 2019, BCYC's revenue was $13.80 million, an increase of 93.40% compared to the previous year's $7.14 million. Losses were -$30.61 million, 40.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is 34.88, which is an increase of 38.03% from the latest price.

Price Target
$34.88
(38.03% upside)
Analyst Consensus: Buy